Obsidian's amsoki-cel Hits 67% Response Rate in Advanced Melanoma
OBX sits 30% above its 52-week low of $9.6.
Summary
Obsidian reported a 67% objective response rate and 8.3-month median progression-free survival for amsoki-cel in advanced melanoma. Median duration of response was not reached at a median 14.3 months of follow-up, so durability is still unproven. This is an interim update from the ongoing Phase 1/2 Agni-01 study, not a pivotal readout, and the release gives no prior-period or control-group comparison. Enrollment is expected to finish by Q1 2027, with topline data by year-end 2027 — that readout is the next real evidence point for the program.
At the time of this announcement, OBX was trading at $12.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $770.9M. The 52-week trading range was $9.60 to $49.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.